



## PRIOR AUTHORIZATION REQUEST

### Chelating Agents – Oral Iron Chelators

#### Patient Information:

Name:	
Member ID:	
Address:	
City, State, Zip:	
Date of Birth:	

#### Prescriber Information:

Name:	
NPI:	
Phone Number:	
Fax Number:	
Address:	
City, State, Zip:	

#### Requested Medication

Rx Name:	
Rx Strength:	
Rx Quantity:	
Rx Frequency:	
Rx Route of Administration:	
Diagnosis and ICD Code:	

Your patient's prescription benefit requires that we review certain requests for coverage with the prescriber. You have prescribed a medication for your patient that requires Prior Authorization before benefit coverage or coverage of additional quantities can be provided. Please complete the following questions then fax this form to the toll-free number listed below. Upon receipt of the completed form, prescription benefit coverage will be determined based on the plan's rules.

#### **SECTION A:** Please note that supporting clinical documentation is required for **ALL** PA requests.

- |   |   |     |    |
|---|---|-----|----|
| 1 | Is the medication being prescribed by or in consultation with hematologist?<br>[If no, no further questions.]   | Yes | No |
| 2 | What drug is being requested?<br><input type="checkbox"/> Deferiprone (If checked, go to 9)<br><br><input type="checkbox"/> Ferriprox TABLET, Ferriprox (3 times a day) TABLET, Ferriprox (2 times a day) TABLET, MODIFIED RELEASE (If checked, go to 3)<br><br><input type="checkbox"/> Ferriprox SOLUTION, ORAL (If checked, go to 4)<br><br><input type="checkbox"/> Deferasirox GRANULES IN PACKET (EA) (If checked, go to 4) |     |    |

If you have any  
questions, call:  
1-888-258-8250

## PRIOR AUTHORIZATION REQUEST

☐ Jadenu sprinkle GRANULES IN PACKET (EA) (If checked, go to 6)

☐ Jadenu TABLET (If checked, go to 3)

☐ Deferasirox TABLET (If checked, go to 9)

☐ Exjade TABLET, DISPERSIBLE (If checked, go to 6)

☐ Deferasirox TABLET, DISPERSIBLE (If checked, go to 4)

3	Has the patient had a trial and failure with generic products of the requested medication?	Yes	No
---	--	-----	----

[NOTE: Generic for Ferriprox is deferiprone; Generic for Jadenu is deferasirox.]

[If no, no further questions.]

[If yes, skip to question 9.]

4	Does the patient have dysphagia or is unable to swallow capsules/tablets?	Yes	No
---	---	-----	----

[If yes, skip to question 9.]

5	Is the patient using a feeding tube to take medications?	Yes	No
---	--	-----	----

[If no, no further questions.]

[If yes, skip to question 9.]

6	Has the patient had a trial and failure with generic products of the requested medication?	Yes	No
---	--	-----	----

[NOTE: Generic for Jadenu and Exjade is deferasirox.]

[If no, no further questions.]

7	Does the patient have dysphagia or is unable to swallow capsules/tablets?	Yes	No
---	---	-----	----

[If yes, skip to question 9.]

8	Is the patient using a feeding tube to take medications?	Yes	No
---	--	-----	----

[If no, no further questions.]

9 What is the indication or diagnosis?

☐ Chronic iron overload due to blood transfusions (If checked, go to 28)

☐ Chronic iron overload in non-transfusion-dependent thalassemia syndromes (If checked, go to 18)

☐ Transfusional chronic iron overload with thalassemia syndromes (If checked, go to 10)

☐ Transfusional chronic iron overload with sickle cell disease or other anemias (If checked, go to 10)

☐ Other (If checked, no further questions)

**If you have any  
questions, call:  
1-888-258-8250**

## PRIOR AUTHORIZATION REQUEST

- |    |   |     |    |
|----|---|-----|----|
| 10 | What drug is being requested?<br><input type="checkbox"/> Deferasirox, Exjade, Jadenu, Jadenu sprinkle (If checked, no further questions)<br><br><input type="checkbox"/> Ferriprox TABLET, Deferiprone TABLET (If checked, go to 11)<br><br><input type="checkbox"/> Ferriprox SOLUTION, ORAL (If checked, go to 12) |     |    |
| 11 | Is the patient greater than or equal to 8 years of age?<br>[If no, no further questions.]<br>[If yes, skip to question 13.]   | Yes | No |
| 12 | Is the patient greater than or equal to 3 years of age?<br>[If no, no further questions.]   | Yes | No |
| 13 | Is the request a continuation of therapy?<br>[If yes, skip to question 16.]   | Yes | No |
| 14 | Has documentation been submitted to confirm that the patient has a serum ferritin level greater than 1,000 micrograms/liter (mcg/L) prior to starting chelating therapy? ACTION REQUIRED: Submit supporting documentation.<br>[If no, no further questions.]  | Yes | No |
| 15 | Has the patient's Absolute neutrophil count (ANC) been measured before initiating therapy and will be measured weekly thereafter?<br>[No further questions.]  | Yes | No |
| 16 | Is the patient's Absolute neutrophil count (ANC) measured weekly?<br>[If no, no further questions.]   | Yes | No |
| 17 | Is the patient's serum ferritin concentration levels being measured every 2 to 3 months?<br>[If no, no further questions.]<br>[If yes, skip to question 34.]  | Yes | No |
| 18 | What drug is being requested?<br><input type="checkbox"/> Deferasirox, Exjade, Jadenu, Jadenu sprinkle (If checked, go to 22)<br><br><input type="checkbox"/> Deferiprone, Ferriprox (If checked, go to 19)   |     |    |
| 19 | Is the request a continuation of therapy?<br>[If yes, skip to question 34.]   | Yes | No |
| 20 | Does the patient have a documented diagnosis of thalassemia disorder?<br>[If no, no further questions.]   | Yes | No |
| 21 | Has documentation been submitted to confirm that the patient has a serum ferritin level greater than 300 micrograms/liter (mcg/L) prior to starting chelating therapy?  | Yes | No |

**If you have any  
 questions, call:  
 1-888-258-8250**

## PRIOR AUTHORIZATION REQUEST

ACTION REQUIRED: Submit supporting documentation.  
[No further questions.]

22	Is the request a continuation of therapy? [If yes, skip to question 26.]	Yes	No
23	Is the patient greater than or equal to 10 years of age? [If no, no further questions.]	Yes	No
24	Has documentation been submitted to confirm that the patient has a liver iron concentration (LIC) of at least 5 milligrams iron per gram of liver dry weight (mg Fe/g dw)? ACTION REQUIRED: Submit supporting documentation. [If no, no further questions.]	Yes	No
25	Has documentation been submitted to confirm that the patient has a serum ferritin level greater than 300 micrograms/liter (mcg/L) prior to starting chelating therapy? ACTION REQUIRED: Submit supporting documentation. [If no, no further questions.] [If yes, skip to question 33.]	Yes	No
26	Is the patient's blood counts, liver function, renal function, and ferritin levels being monitored monthly? [If no, no further questions.]	Yes	No
27	Has documentation been submitted to confirm that the patient has a liver iron concentration (LIC) of at least 3 milligrams iron per gram of liver dry weight (mg Fe/g dw)? ACTION REQUIRED: Submit supporting documentation. [If no, no further questions.] [If yes, skip to question 34.]	Yes	No
28	Is the patient greater than or equal to 2 years of age? [If no, no further questions.]	Yes	No
29	Does the prescriber agree to monitor the patient's blood counts, liver function, renal function, and ferritin levels monthly? [If no, no further questions.]	Yes	No
30	Is the request a continuation of therapy? [If yes, skip to question 34.]	Yes	No
31	Is the patient receiving blood transfusions at regular intervals for a chronic condition? [NOTE: Examples of chronic conditions include thalassemia syndromes, myelodysplastic syndrome, chronic anemia, and sickle cell disease] [If no, no further questions.]	Yes	No
32	Has documentation been submitted to confirm that the patient has a serum ferritin level greater than 1,000 micrograms/liter (mcg/L) prior to starting chelating	Yes	No

**If you have any  
questions, call:  
1-888-258-8250**



## PRIOR AUTHORIZATION REQUEST

therapy? ACTION REQUIRED: Submit supporting documentation.  
[If no, no further questions.]

- |    |  |     |    |
|----|--|-----|----|
| 33 | Does the patient have an estimated glomerular filtration rate (eGFR) greater than 40 mL/min/1.73 m <sup>2</sup> ?<br>[No further questions.]   | Yes | No |
| 34 | Did the patient have a documented clinically significant response as determined by the prescriber?<br>[NOTE: Examples of response of therapy include reduction in serum ferritin levels, stable disease, and reduced organ iron load.] | Yes | No |

***Please document the diagnoses, symptoms, and/or any other information important to this review:***

### **SECTION B:** Physician Signature

PHYSICIAN SIGNATURE

DATE

**FAX COMPLETED FORM TO: 1-833-896-0656**

**Disclaimer:** An authorization is not a guarantee of payment. Member must be eligible at the time services are rendered. Services must be a covered Health Plan Benefit and medically necessary with prior authorization as per Plan policy and procedures.

**Confidentiality:** The information contained in this transmission is confidential and may be protected under the Health Insurance Portability and Accountability Act of 1996. If you are not the intended recipient any use, distribution, or copying is strictly prohibited. If you have received this facsimile in error, please notify us immediately and destroy this document.

**If you have any  
questions, call:  
1-888-258-8250**